Clinical trials: Tumor Immunity
Mantle-cell Lymphoma, B Cell Chronic Lymphocytic Leukemia
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
Mantle-cell Lymphoma (MCL) is a B-cell non-Hodgkin's lymphoma (NHL) with heterogeneous behavior,ranging from indolent phenotype to highly aggressive and drug resistant cases with dismal prognosis.Disease progression and drug…
- Trial name
- NCT05888701
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Milano Bicocca
Renal Cell Carcinoma, GIST
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal…
- Trial name
- NCT00979381
- Testing
- influenza vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Breast Cancer
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2
RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2.
- Trial name
- NCT00363012
- Testing
- HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
Prostate Cancer
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
This study intents to provide an initial evaluation of the utility of positron emission tomography and magnetic resonance (PET/MR) imaging measures for the prediction of immunological response to Sipuleucel T (SipT) therapy.
- Trial name
- NCT02042053
- Testing
- PET/CT, PET/MRI
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT
At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response.
- Trial name
- IOSCAR (NCT04624828)
- Testing
- Radiotherapy, androgen deprivation therapy (ADT), immune evaluation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Clinico Humanitas
Papillomavirus Infections
PApillomavirus in REnal Transplant Patient
The main goal of project is to study the distribution of HPV genotypes in the anogenital area and peripheral humoral immune responses HPV (total and neutralizing Ab) before and after renal transplantation.
- Trial name
- PATRE (NCT02845739)
- Testing
- Kidney transplanted patients
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Bladder Cancer
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
- Trial name
- NCT02365207
- Testing
- BCG strain of Mycobacterium bovis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Skin Inflammation, Skin Melanoma
Effects of Ultraviolet B Exposure Using a Ultraviolet Skin Care Device on Vitamin D Production and Immune Response in Healthy Adults
Vitamin D regulates various physiological functions, including calcium homeostasis, bone health, and potentially reducing cancer risks.
- Trial name
- NCT06625918
- Testing
- Ultraviolet B exposure to produce vitamin D synthesis
- Where
- South Korea
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wonju Severance Christian Hospital
Cancer
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
- Trial name
- I-SPARC (NCT05075538)
- Testing
- Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1
- Where
- 2 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer, Surgery
Human Blood Specimen Collection to Evaluate Immune Cell Function
Natural killer (NK) cells are leukocytes of the innate immune system and play a central role in the control of cancer metastases.
- Conditions
- Colorectal Cancer, Surgery, Perioperative Care
- Trial name
- NCT03422120
- Testing
- Natural Killer Cell Activity Assay
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06909110
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jessie L. Alexander
Actinic Keratoses
Comparing Immune Responses to Topical Imiquimod
The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene…
- Trial name
- NCT04809662
- Testing
- Imiquimod
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Neoplasms
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not…
- Trial name
- NCT00095160
- Testing
- 852A
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Immunization, HPV Infection
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response.
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Trial name
- NCT05672927
- Testing
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Lung Cancer
Radio-Immuno-Modulation in Lung Cancer
This project will assess the feasibility of treating advanced cancer using the immune system, without any anti-cancer drug. In this pilot study, the investigators propose combining low-dose radiotherapy, in lung cancer patients…
- Trial name
- RIM (NCT02579005)
- Testing
- Patients with a living donor, Patients with a UCB donor
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Breast Cancer, Prostate Cancer
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
The objective of this project is to test the association between Cognitive Behavioral Therapy for Insomnia dose (number of sessions), severity of cancer related fatigue, and levels of innate immunity biomarkers.
- Trial name
- NCT06604247
- Testing
- Cognitive Behavioral therapy for insomnia (CBT-I)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
This study is a prospective, randomized controlled, multicenter clinical study. The purpose of this study is to explore the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with second-line regorafenib…
- Trial name
- NCT05233358
- Testing
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib
- Volunteers
- 176 people
- Sponsor
- The Central Hospital of Lishui City
Cervical Cancer, Benign Tumor of Uterus
Mechanisms and Biomarkers for Tumor Immunogenicity Modulation in Cervical Cancer
This study aims to investigate mechanisms that dictate tumor immunogenicity and to explore potential biomarkers that could help predict changes of tumor immunogenicity and therapeutic response in patients with cervical cancer…
- Trial name
- NCT05188716
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chuangzhen Chen
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
The reconstitution of a functioning immune system after allogeneic stem cell transplantation takes months to years. Particularly memory B-lymphocytes reconstitute poorly with the current conditioning regimes.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- B-cell therapy (NCT02007811)
- Testing
- allogeneic donor derived B-lymphocytes
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Advanced Cancer
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen…
- Trial name
- PRIMO (NCT04270864)
- Testing
- Ipilimumab, Nivolumab, Tilsotolimod
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris